Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) reported preliminary data from an ongoing Phase 2 trial evaluating RM-718, an investigational once-weekly MC4R ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE